Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint

Journal of Virology

Volumn 72, Issue 2, 1998, Pages 1131-1137

  Thomas, Jennifer T ^a   Laimins, Laimonis A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOCODAZOLE; ONCOPROTEIN; PROTEIN P53; VIRUS PROTEIN;

ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; GROWTH REGULATION; MITOSIS; MITOSIS SPINDLE; NONHUMAN; PRIORITY JOURNAL; WART VIRUS;

EID: 0031930282     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.2.1131-1137.1998     Document Type: Article

References (69)

1. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461-468.
2. Cahilly-Snyder, L., T. Yang-Feng, U. Francke, and D. L. George. 1987. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol. Genet. 13:235-244.
3. Chellappan, S., S. Hiebert, M. Mudryj, J. Horowitz, and J. Nevins. 1991. The E2F transcription factor is a cellular target for the Rb protein. Cell 65:1053-1061.
4. Chen, C., J. D. Oliner, Q. Zhan, A. J. Fornace, Jr., B. Vogelstein, and M. B. Kastan. 1994. Interaction between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA 91:2684-2688.
5. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16:2445-2452.
6. Cross, S. M., C. A. Sanchez, C. A. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W. H. Raskind, and B. J. Reid. 1995. A p53-dependent mouse spindle checkpoint. Science 267:1353-1356.
7. Davies, R., R. Hicks, T. Crook, J. Morris, and K. Vousden. 1993 Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J. Virol. 67:2521-2528.
8. Demers, G., S. Foster, C. Halbert, and D. Galloway. 1994. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7 protein. Proc. Natl. Acad. Sci. USA 91:4382-4386.
9. Demers, G. W., E. Espling, J. B. Harry, B. G. Etscheid, and D. A. Galloway. 1996. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J. Virol. 70:6862-6869.
10. Demers, G. W., C. L. Halbert, and D. A. Galloway. 1994. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology 198:169-174.
11. de Villiers, E.-M. 1994. Human pathogenic papillomavirus types: an update. Curr. Top. Microbiol. Immunol. 186:1-12.
12. Di Leonardo, A., S. H. Khan, S. P. Linke, V. Greco, G. Seidita, and G. M. Wahl. 1997. DNA replication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57:1013-1019.
13. Dyson, N., P. Guida, K. Munger, and E. Harlow. 1992. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interactions with the same set of cellular proteins. Science 243:934-936.
14. Dyson, N., P. Howley, K. Munger, and E. Harlow. 1989. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937.
15. El-Diery, W. S., T. Tokino, D. B. Velculescu, D. B. Levy, J. M. Parsons, D. L. Trent, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
16. Fakharzadeh, S. S., S. P. Trusko, and D. L. George. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1565-1569.
17. Finlay, C. A. 1993. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13:301-306.
18. Foster, S. A., G. W. Demers, B. G. Etscheid, and D. A. Galloway. 1994. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68:5698-5705.
19. Frattini, M. G., H. B. Lim, and L. A. Laimins. 1996. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc. Natl. Acad. Sci. USA 93:3062-3067.
20. Gu, Z., D. Pim, S. Labrecque, L. Banks, and G. Matlashewski. 1994. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. Oncogene 9:629-633.
21. Halbert, C. L., G. W. Demers, and D. A. Galloway. 1991. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:473-478.
22. Halbert, C. L., G. W. Demers, and D. A. Galloway. 1992. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 66:2125-2134.
23. Haupt, Y., Y. Barak, and M. Oren. 1996. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15:1596-1606.
24. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
25. Hickman, E., S. Picksley, and K. H. Vousden. 1994. Cells expressing HPV 16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 9:2177-2181.
26. Hickman, E. S., S. Bates, and K. H. Vousden. 1997. Perturbation of the p53 response by human papillomavirus type 16 E7. J. Virol. 71:3710-3718.
27. Hoppe-Seyler, F., and K. Butz. 1993. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papiliomavirus type 16 E6, human mdm-2, and mutant p53. J. Virol. 67:3111-3117.
28. Howley, P. M. 1996. Papillomavirinae: the viruses and their replication, p. 947-978. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fundamental virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
29. Huibregtse, J. M., M. Scheffner, and P. M. Howley. 1991. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10:4126-4135.
30. Juven, T., Y. Barak, A. Zauberman, D. George, and M. Oren. 1993. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416.
31. Kessis, T. D., R. J. Slebos, W. G. Nelson, M. B. Kastan, B. S. Plunkett, S. M. Han, A. T. Lorincz, L. Hedrick, and K. R. Cho. 1993. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 90:3988-3992.
32. Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.
33. Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
34. Laimins, L. A. 1993. The biology of human papillomavirus: from warts to cancer Infect. Agents Dis. 2:74-86.
35. Landers, J. E., S. L. Cassel, and D. L. George. 1997. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild type p53 protein. Cancer Res. 57:3562-3568
36. Lane, D. P. 1992. p53, guardian of the genome. Nature 358:15-16.
37. Lechner, M. S., and L. A. Laimins. 1994. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 68:4262-4273.
38. Lechner, M. S., D. H. Mack, A. B. Finicle, T. Crook, K. H. Vousden, and L. A. Laimins. 1992. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 11:3045-3052.
39. Levine, A. J., J. Momand, and C. A. Finlay. 1991. The p53 tumour suppressor gene. Nature 351:453-456.
40. Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935.
41. Lowy, D. R., R. Kirnbauer, and J. T. Schiller. 1994. Genital human papillomavirus infection. Proc. Natl. Acad. Sci. USA 91:2436-2440.
42. Lundgren, K., R. Montes de Oca Luna, Y. B. McNeill, E. P. Emerick, B. Spencer, C. R. Barfield, G. Lozano, M. P. Rosenberg, and C. A. Finlay. 1997. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 11:714-725.
43. Martin, K., D. Trouche, C. Hagemeier, T. S. Sorenson, N. B. La Thangue, and T. Kouzarides. 1995. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375:691-694.
44. Meyers, C., M. G. Frattini, J. B. Hudson, and L. A. Laimins. 1992. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257:971-973.
45. Meyers, C., and L. A. Laimins. 1994. In vitro systems for the study and propagation of human papillomaviruses. Curr. Top. Microbiol. Immunol. 186:199-215.
46. Mietz, J. A., T. Unger, J. M. Huibregtse, and P. M. Howley. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11:5013-5020.
47. Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
48. 1 arrest induced by serum deprivation and by the cell cycle inhibitor p21. J. Virol. 71:3451-3457.
49. Munger, K., M. Scheffner, J. M. Huibregtse, and P. M. Howley. 1992. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv. 12:197-217.
50. Munger, K., B. Werness, N. Dyson, W. Phelps, E. Harlow, and P. Howley. 1989. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8:4099-4105.
51. Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
52. Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860.
53. Reznikoff, C. A., C. Belair, E. Savelieva, Y. Zhai, K. Pfeifer, T. Yeager, K. J. Thompson, S. DeVries, C. Bindley, M. A. Newton, G. Sekhon, and F. Waldman. 1994. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev. 8:2227-2240.
54. Ruesch, M. N., and L. A. Laimins. 1997. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J. Virol. 71:5570-5578.
55. Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
56. Scheffner, M., H. Romanczuk, K. Munger, J. M. Huibregtse, J. A. Mietz, and P. M. Howley. 1994. Functions of human papillomavirus proteins. Curr. Top. Microbiol. Immunol. 186:83-99.
57. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
58. Schiffman, M. H. 1994. Epidemiology of cervical human papillomavirus infections. Curr. Top. Microbiol. Immunol. 186:55-81.
59. Slebos, R. J., M. H. Lee, B. S. Plunkett, T. D. Kessis, B. O. Williams, T. Jacks, L. Hedrick, M. B. Kastan, and K. R. Cho. 1994. p53-dependent G1 arrest involves pRb-related proteins and is disrupted by the papillomavirus 16 E7 oncoprotein. Proe. Natl. Acad. Sci. USA 91:5320-5324.
60. Vousden, K. H. 1994. Interactions between papillomavirus proteins and tumor suppressor gene products. Adv. Cancer Res. 64:1-24.
61. Waldman, T., C. Lengauer, K. W. Kinzler, and B. Vogelstein. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713-716.
62. Weinberg, R. A. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
63. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 proteins with p53. Science 248:76-79.
64. White, A. E., E. M. Livanos, and T. D. Tlsty. 1994. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev. 8:666-677.
65. Wu, X., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
66. Xiao, Z., J. Chen, A. J. Levine, N. Modjtahedi, J. Xing, W. R. Sellers, and D. M. Livingston. 1995. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698.
67. Xiong, Y., D. Kuppuswamy, Y. Li, E. M. Livanos, M. Hixon, A. White, D. Beach, and T. D. Tlsty. 1996. Alteration of cell cycle kinase complexes in human papillomavirus E6-and E7-expressing fibroblasts precedes neoplastic transformation. J. Virol. 70:999-1008.
68. Yin, Y., M. A. Tainsky, F. Z. Bischoff, L. C. Strong, and G. M. Wahl. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948.
69. zur Hausen, H., and E. De Villiers. 1994. Human papillomaviruses. Annu. Rev. Microbiol. 48:427-447.